Exploris Health

What Exploris Health does

Exploris Health AG is a Swiss medical technology company founded in 2018 and headquartered in Wallisellen, Switzerland, that develops AI-based diagnostic and therapy solutions for cardiovascular disease. Its flagship product, Cardio Explorer, is a CE-marked, IVDR Class B software-as-a-medical-device that calculates a personalized pre-test probability for obstructive coronary artery disease by combining 15 laboratory blood biomarkers, ECG data, symptoms, and clinical risk factors. The product is positioned as a non-invasive rule-out tool for primary care, validated in three peer-reviewed studies with over 2,000 patients and achieving an AUC of 0.87 — comparable to cardiac CT and MRI — and serves hospitals, cardiologists, general practitioners, preventive medicine centers, corporate health programs, and patients with suspected chronic coronary syndrome across Switzerland, Germany, and the UAE.

The portfolio is anchored by Cardio Explorer and extends to Heart Failure Explorer (a personalized heart failure therapy solution under development) and an 'AI as a Service' offering built on the AI-X platform. The proprietary AI-enhanced multi-marker algorithm ingests structured clinical data and exposes an API for integration with electronic health records — most recently connected to Switzerland's electronic patient dossier through Post Sanela Health AG. Clinical validation has been conducted with academic partners including Universitätsspital Basel, Maastricht University Medical Centre (696-patient CVC study), and HGZ Bad Bevensen, and the algorithm has received EQUAL CARE certification for gender-balanced diagnostic performance.

Exploris Health generates revenue primarily through per-test transaction fees for Cardio Explorer screenings (approximately CHF 350 per screening in Switzerland) and increasingly through insurance reimbursement and strategic partnerships. The product is included in the supplementary coverage of major Swiss health insurers — Helsana Primeo (90% reimbursement up to CHF 5,000 per year) and CSS Gesundheitskonto — which broadens patient access and drives volume. Distribution is hybrid: direct physician and clinic sales in Switzerland and Germany, channel partners such as Sana Praevention (Munich/Frankfurt) and Alfadiag (UAE), and a flagship distribution agreement with Roche for global reach. The company has been awarded ISO 13485 certification (BSI, October 2025), the DMEA nova Award (2024), the Swiss InsurTech Hub Impact on Digital Health award (2024), and the InsureNXT Innovation Award (2025).

Name

Exploris Health

Legal name

Exploris Health AG

Website

https://explorishealth.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Exploris Health AG is a Swiss medical technology company that develops AI-based cardiovascular diagnostics. Its Cardio Explorer is an IVDR-cleared, non-invasive AI test using blood biomarkers and clinical data to detect coronary artery disease, serving hospitals, clinics, physicians, and insurers across Europe and the Middle East.

Ownership category

akta.pro rank

Product category

Cardiovascular Diagnostic Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Software Publishers (5132)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Services-Prepackaged Software (7372)

akta.pro primary industry

SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE)

akta.pro secondary industries

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Heart Failure & Transplant Cardiology (HLAKABAD)

Keywords

• Cardiac diagnostics software
• Coronary artery disease detection
• AI medical algorithms
• Cardiovascular risk assessment
• Heart failure management

Headquarters

HQ city

Wallisellen

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Cardio Explorer Diagnostic Testing: Revenue generated from Cardio Explorer diagnostic tests performed at partner clinics and healthcare providers. Tests are ordered by physicians and billed through healthcare systems or reimbursed by insurance. Pricing approximately CHF 350 per screening in Switzerland.
2. Insurance Reimbursement: Cardio Explorer is included in insurance reimbursement packages including Helsana Primeo (90% cost coverage) and CSS Gesundheitskonto. This enables patient access while generating revenue through insurance claim processing.
3. Strategic Partnerships and Licensing: Partnership with Roche aims to enable global access to Cardio Explorer, potentially including licensing arrangements for international market expansion.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Exploris Health develops and sells AI-based medical device software for cardiovascular diagnostics and therapy. The flagship product, Cardio Explorer, is a CE-marked and IVDR Class B cleared Software as Medical Device (SaMD) that non-invasively detects obstructive coronary artery disease by combining 15 blood biomarkers, ECG data, symptoms, and clinical risk factors into a personalized pre-test probability score (AUC 0.87). The company also offers Heart Failure Explorer for personalized heart failure therapy and custom AI development services through its AI-X platform.

Product overview

Exploris Health is a Swiss medical technology company offering AI-based diagnostic and therapy solutions. The core product portfolio consists of Cardio Explorer (an IVDR-cleared AI diagnostic test for coronary artery disease), Heart Failure Explorer (personalized heart failure therapy), and AI as a Service capabilities built on the AI-X Platform. The company leverages proprietary multi-marker algorithms combining blood biomarkers, ECG data, and clinical parameters to provide personalized cardiovascular risk assessment. Cardio Explorer serves as the primary commercially available product, while Heart Failure Explorer and custom AI services are under development.

Differentiator

Problem solved

Functional benefit

Brands

• Cardio Explorer: AI-based diagnostic test for detecting obstructive coronary artery disease (CAD) and assessing heart attack risk. Non-invasive test using blood biomarkers, ECG data, symptoms, and clinical risk factors. CE-marked and validated in three clinical studies.
• Heart Failure Explorer
• KI als Service (AI as a Service)

Products and services

• Cardio Explorer A non-invasive AI-based diagnostic test (Software as Medical Device) that calculates personalized pre-test probability for obstructive coronary artery disease (CAD) using 15 blood biomarkers, ECG data, symptoms, and clinical risk factors. CE-marked and IVDR Class B cleared for use in the EU and UK. For physicians, cardiologists, hospitals, and preventive medicine centers.
• Heart Failure Explorer A personalized therapy solution for heart failure (Herzinsuffizienz) that enables patient self-treatment and optimizes therapy management. Part of Exploris Health's AI-based diagnostic and therapy solutions portfolio alongside Cardio Explorer.
• KI als Service (AI as a Service) Custom AI development services enabling rapid analysis of complex data structures and development of new applications through Exploris Health's AI-X platform. Provides data science and predictive modeling capabilities for healthcare and other sectors.
• AI-X Platform The technology platform supporting all Exploris Health AI solutions. Enables rapid analysis of complex data structures and development of new AI applications for healthcare diagnostics and therapy optimization. Sold as the foundation for the KI als Service offering.

Quantifiable outcome

• 96 out of 100 patients correctly identified as not having obstructive CAD when selecting low- and very-low-risk patients for rule-out
• +4 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature4 records

Partnerships

16 partnerships are on record, tiered core, flagship and minor.

• Post Sanela Health AGcoreTechnology or Integration · 18 November 2025Integration of Cardio Explorer into the electronic patient dossier (EPD) in Switzerland. Post Sanela Health AG offers EPD through Sanela Stammgemeinschaft, supporting secure healthcare networking. Results will be automatically and securely stored and accessible to patients and healthcare providers.
• RocheflagshipStrategic or Co-development Partner · 30 September 2025Strategic collaboration to improve cardiac diagnostics and enable worldwide access to Cardio Explorer. Partnership aims to contribute to timely diagnosis of coronary heart disease (KHK). Roche commits to investing in innovative solutions and AI to support efficient, evidence-based clinical decision-making.
• Medcare Hospitals & Medical CentrescoreStrategic or Co-development Partner · 23 September 2025Medcare Hospitals in UAE deploying Cardio Explorer for early detection of coronary heart disease. Dr. Brajesh Mittal, Head of Cardiology at Medcare Hospital Al Safa, noted Cardio Explorer as a 'game-changer for early intervention' enabling proactive care.
• AlfadiagminorChannel Partner/ Reseller/ DistributorSales partner in UAE region facilitating distribution and implementation of Cardio Explorer at Medcare Hospitals and other regional healthcare providers.
• Sana PraeventioncoreChannel Partner/ Reseller/ DistributorSana Praevention offers Cardio Explorer KI-Herz-Check-Up at Munich and Frankfurt locations as part of health check-up services for individuals and corporate clients. Part of Sana Kliniken AG, one of largest healthcare providers in German-speaking region.
• HelsanacoreChannel Partner/ Reseller/ DistributorHelsana Primeo supplementary insurance includes Cardio Explorer with 90% cost reimbursement. Up to CHF 5,000 per calendar year reimbursed for insured customers. First insurance partner to include Cardio Explorer in coverage.
• CSScoreChannel Partner/ Reseller/ DistributorCardio Explorer included in CSS 'Gesundheitskonto' reimbursement package. CSS supports innovative offerings to improve products for insured persons. CSS representative noted commitment to shaping future of healthcare system.
• Herz-Hirn-AllianzminorStrategic or Co-development PartnerMembership in alliance of leading healthcare stakeholders including medical societies, patient organizations, health insurance companies, and industry representatives. Goal to reduce cardiovascular events in Germany by 30% by 2030.
• 5-HT Chemistry & HealthminorGTM or Marketing PartnerMembership platform connecting successful global players and hidden champions in chemistry and health with innovative startups. Provides networking, cooperation, and co-development opportunities with focus on digital innovation in Germany.
• DayOne Health 4.0 AcceleratorminorGTM or Marketing PartnerSelected for DayOne Health 4.0 Accelerator Cohort 2024, hosted by Roche. Access to accelerator resources, mentorship, and healthcare innovation network.
• Universitätsspital BaselcoreStrategic or Co-development PartnerClinical validation partner with Prof. Michael Zellweger serving on Cardio Explorer Medical Advisory Board as Head of Non-Invasive Cardiology. Active research collaboration in non-invasive cardiac imaging and AI applications.
• Maastricht University Medical Centre (MUMC+)coreStrategic or Co-development PartnerClinical validation site for CVC study with 696 patients. Prof. Hans-Peter Brunner-La Rocca serves on Medical Advisory Board as Vice Chairman, Department of Cardiology. Research collaboration in cardiology and heart failure.
• Herz- und Gefässzentrum (HGZ) Bad BevensencoreStrategic or Co-development PartnerClinical partner with Prof. Bjoern Andrew Remppis contributing to Cardio Explorer publications. His work in molecular heart failure research and troponin-T test development influenced cardiology field.
• Boehringer IngelheimminorStrategic or Co-development PartnerPharmaceutical partner shown in company logos, part of broader healthcare ecosystem partnerships for cardiovascular disease management.
• MedbaseminorChannel Partner/ Reseller/ DistributorHealthcare provider partner for Cardio Explorer campaigns and distribution in Swiss market.
• HirslandenminorChannel Partner/ Reseller/ DistributorSwiss hospital group partner shown in company logos for healthcare delivery partnerships.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

Broad incumbents

• Siemens Healthineers: Siemens Healthineers provides cardiac CT, MRI, and AI-enabled diagnostic software, offering broad incumbency alternatives to Cardio Explorer's non-imaging CAD pre-screening test.
• GE HealthCare: GE HealthCare is a large incumbent in cardiac imaging, ECG, and AI-augmented diagnostics, providing overlapping but broader alternatives to Cardio Explorer's focused CAD pre-screening.
• Philips: Philips offers cardiac imaging, monitoring, and AI-driven cardiology solutions as part of a broader connected-care portfolio, addressing the same hospital cardiology workflows as Cardio Explorer.

Direct peers

• Cleerly: Cleerly applies AI to coronary CTA to characterize plaque and identify obstructive CAD, competing directly with Cardio Explorer for the pre-screening and risk-stratification step before invasive testing.
• Elucid Bioimaging: Elucid develops AI-based vascular imaging analysis for cardiovascular disease characterization, overlapping with Cardio Explorer's goal of non-invasive CAD detection and risk stratification.
• HeartFlow: HeartFlow provides AI-driven FFR-CT analysis for obstructive coronary artery disease, addressing the same CAD detection workflow as Cardio Explorer but using non-invasive cardiac CT imaging rather than blood biomarkers and ECG.

Emerging players

• Eko Health: Eko Health combines digital stethoscopes and AI-enabled ECG analysis for cardiac screening in primary care, an adjacent but overlapping approach to Cardio Explorer's algorithm-based cardiac assessment.
• AliveCor: AliveCor's KardiaMobile and KardiaAI platforms deliver AI-interpreted consumer ECG for arrhythmia and cardiac risk screening, comparable to Cardio Explorer's goal of broadening access to AI-driven cardiac diagnostics.
• Anumana: Anumana applies AI to ECG signals to surface hidden cardiac conditions, sharing Cardio Explorer's emphasis on algorithmic interpretation of cardiac signals for early disease detection.
• Aidoc: Aidoc provides AI imaging decision-support across multiple specialties including cardiology, competing for the same hospital IT budgets and workflow integration slots that Cardio Explorer targets via its API.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/exploris-health

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exploris Health